OrbiMed

Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.

Leal Therapeutics is a Massachusetts-based company focused on developing innovative therapeutics for patients with significant central nervous system conditions. The company addresses urgent and unmet medical needs by providing precision medicines tailored to improve patient outcomes. Through its dedication to advancing therapeutic services, Leal Therapeutics aims to enhance the quality of care for individuals affected by challenging neurological disorders.

Scorpion Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing next-generation precision oncology technologies for cancer treatment. Founded in 2020, the company specializes in creating targeted small-molecule drugs that interact with validated cancer targets. Its research encompasses therapies aimed at known oncogenes, previously undruggable cancer targets, and novel targets. By integrating technologies across target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics aims to advance a comprehensive pipeline of optimized compounds. The company's goal is to expand the reach of precision medicine, enabling healthcare professionals to offer innovative treatments to a broader range of cancer patients.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for severe hematologic disorders. Founded in 2017, the company specializes in human genetics-based therapeutics that aim to improve red blood cell production in patients suffering from various hematologic diseases. Disc Medicine's pipeline includes therapeutic candidates targeting critical pathways involved in red blood cell biology, such as heme biosynthesis and iron homeostasis. Notable programs include bitopertin, which is being developed for conditions like erythropoietic porphyrias and Diamond-Blackfan anemia. Through its research and development efforts, Disc Medicine seeks to transform the lives of patients affected by these challenging disorders.

Q32 Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for severe autoimmune and inflammatory diseases. Established in 2017, the company aims to address immune system dysregulation, providing treatment options for conditions that currently have limited or inadequate therapies. Q32 Bio's pipeline includes ADX-914, a human anti-IL-7R antibody designed to re-regulate adaptive immune function, and ADX-097, which demonstrates effective distribution to affected tissues and robust efficacy. With a team of experienced scientists and industry professionals, Q32 Bio is dedicated to restoring healthy immune balance through novel biologic therapies that target critical pathways in both the innate and adaptive immune systems.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

Pinnacle Medicines is a peptide drug discovery company located in Doylestown, Pennsylvania. The company specializes in developing peptide-based therapeutics to address unmet medical needs. Utilizing AI-driven drug design tools, Pinnacle Medicines focuses on creating safe and effective treatments for medical applications. Through its innovative approach, the company aims to enhance the availability of convenient and reliable therapeutics for various health challenges.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for severe hematologic disorders. Founded in 2017, the company specializes in human genetics-based therapeutics that aim to improve red blood cell production in patients suffering from various hematologic diseases. Disc Medicine's pipeline includes therapeutic candidates targeting critical pathways involved in red blood cell biology, such as heme biosynthesis and iron homeostasis. Notable programs include bitopertin, which is being developed for conditions like erythropoietic porphyrias and Diamond-Blackfan anemia. Through its research and development efforts, Disc Medicine seeks to transform the lives of patients affected by these challenging disorders.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

PIC Therapeutics, Inc. is a biotechnology company dedicated to innovating cancer treatment through the selective modulation of oncogene translation. Founded in 2016 and based in Boston, Massachusetts, the company focuses on developing therapeutics that target the "master switch" of cancer signaling pathways. By modulating the pre-initiation complex responsible for messenger RNA translation, PIC Therapeutics aims to selectively block the production of oncogene proteins. This precision-based approach has the potential to simultaneously address multiple oncogenic drivers, thereby improving patient outcomes and advancing a new generation of cancer treatments.

Treeline Biosciences is a biotechnology company established in 2021 and based in Stamford, Connecticut. The company focuses on developing transformative precision medicines aimed at treating cancer and other serious health conditions. Utilizing a comprehensive drug discovery platform, Treeline combines mechanistic biology, medicinal chemistry, computational science, structural biology, and protein science to create innovative therapeutic solutions. Through its research and development efforts, Treeline aims to provide effective treatments to improve patient outcomes in oncology and beyond.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for severe hematologic disorders. Founded in 2017, the company specializes in human genetics-based therapeutics that aim to improve red blood cell production in patients suffering from various hematologic diseases. Disc Medicine's pipeline includes therapeutic candidates targeting critical pathways involved in red blood cell biology, such as heme biosynthesis and iron homeostasis. Notable programs include bitopertin, which is being developed for conditions like erythropoietic porphyrias and Diamond-Blackfan anemia. Through its research and development efforts, Disc Medicine seeks to transform the lives of patients affected by these challenging disorders.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. These include a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as Phase Ib and Phase IIa trials focused on severe congenital neutropenia and clear cell renal cell carcinoma, respectively. In addition, X4 Pharmaceuticals is advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 aimed at primary immune deficiencies. The company has also established a license agreement with Abbisko Therapeutics to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.

Leal Therapeutics is a Massachusetts-based company focused on developing innovative therapeutics for patients with significant central nervous system conditions. The company addresses urgent and unmet medical needs by providing precision medicines tailored to improve patient outcomes. Through its dedication to advancing therapeutic services, Leal Therapeutics aims to enhance the quality of care for individuals affected by challenging neurological disorders.

Scout Bio, Inc. is a biotechnology company focused on developing innovative therapies for chronic health conditions in pets, utilizing veterinary biotechnology and gene therapy. Founded in 2016 and based in Philadelphia, Pennsylvania, the company specializes in creating one-time treatments to address significant issues such as anemia linked to chronic kidney disease in cats. Scout Bio employs Adeno-associated viral vector technology to design and deliver protein and monoclonal antibody therapeutics through single intra-muscular injections. The company's mission is to apply advancements from human medicine to improve veterinary care and enhance the quality of life for pets.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for severe hematologic disorders. Founded in 2017, the company specializes in human genetics-based therapeutics that aim to improve red blood cell production in patients suffering from various hematologic diseases. Disc Medicine's pipeline includes therapeutic candidates targeting critical pathways involved in red blood cell biology, such as heme biosynthesis and iron homeostasis. Notable programs include bitopertin, which is being developed for conditions like erythropoietic porphyrias and Diamond-Blackfan anemia. Through its research and development efforts, Disc Medicine seeks to transform the lives of patients affected by these challenging disorders.

Carrot Fertility, Inc. specializes in providing comprehensive fertility benefits services to employers, supporting employees throughout their fertility healthcare journey on a global scale. The company's offerings include services such as egg freezing, in vitro fertilization, adoption, donor and gestational carrier services, as well as a premium pharmacy experience for fertility medications through Carrot Rx. Additionally, Carrot Pregnancy provides virtual access to experts and on-demand doctor-approved content, while the Carrot Card allows employees to use a flexible debit card for their fertility-related expenses. By customizing these benefits, Carrot Fertility aims to deliver financial, medical, and emotional support for individuals pursuing parenthood. Founded in 2015 and headquartered in San Francisco, California, the company also maintains offices in Chicago, New York, Dublin, Geneva, Tokyo, and Seoul.

GentiBio, Inc. is a biotherapeutics company focused on developing engineered regulatory T cells (EngTregs) aimed at treating autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and headquartered in Boston, Massachusetts, with additional locations in Israel and Seattle, GentiBio utilizes a proprietary platform that combines autologous and allogeneic EngTregs technologies. This innovative approach is designed to restore immune tolerance and address limitations present in current regulatory T-cell therapies. By targeting the underlying causes of diseases related to immune system dysfunction, GentiBio aims to provide effective therapeutic solutions for conditions that arise from immune system overshooting or malfunctioning. The company was co-founded by experts in Treg biology and synthetic immunology, positioning it at the forefront of this emerging field.

XtalPi Inc. is a pharmaceutical technology company that focuses on digital drug development solutions, leveraging quantum mechanics and artificial intelligence to enhance the efficiency of drug research and development. Founded in 2014 by a group of quantum physicists at MIT, the company has developed its Intelligent Digital Drug Discovery and Development (ID4) platform, which integrates advanced cloud computing algorithms to aid pharmaceutical firms in critical stages of drug R&D. XtalPi offers various tools, including XtalForc for visual force field calculations, XtalVision for crystal structure predictions, and Renova for platform support of its AI research initiatives. Its comprehensive services encompass crystal structure determination, solid-state testing, small molecule drug design, and collaborations in antibody and peptide research. Based in Cambridge, Massachusetts, with additional offices in China, XtalPi has established strategic partnerships with leading international pharmaceutical companies, demonstrating the broad applicability and recognition of its innovative technologies across the pharmaceutical value chain.

Turnstone Biologics Inc. is a clinical-stage biotechnology company based in Ottawa, Canada, with an additional office in New York. Founded in 2015, the company is dedicated to advancing innovative viral immunotherapies aimed at improving cancer patient survival. Its lead product, RIVAL-01, utilizes a vaccinia virus backbone that encodes several immunomodulators, including Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine, which work together to enhance immune activity and optimize the tumor microenvironment for effective cancer treatment. Additionally, Turnstone Biologics is developing next-generation tumor-infiltrating lymphocyte (TIL) therapies by isolating and expanding the most potent and tumor-reactive T cells from patients' tumors, thereby harnessing the body's own immune system to combat solid tumors. Through these innovative approaches, Turnstone Biologics aims to deliver breakthrough cancer immunotherapies that significantly improve clinical outcomes for patients.

Biocytogen LLC is a biotechnology company based in Worcester, Massachusetts, that specializes in developing gene-targeted animal models for life science research. Founded in 2008, the company offers a range of services, including customized and off-the-shelf mouse models, phenotype analysis, and advanced gene-editing techniques. Its products encompass various types of mice, such as knockin and knockout models, as well as humanized mice, catering to diverse research areas including immunology, neurology, cancer, and infectious diseases. Biocytogen also operates a state-of-the-art animal facility to support its integrated platform for efficient antibody drug discovery and validation. The company collaborates with leading pharmaceutical and biotechnology firms to enhance preclinical research and development processes in the biomedical field.

Magenta Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies to enhance stem cell transplantation for patients with blood cancers, genetic diseases, and autoimmune disorders. The company aims to improve the safety and efficacy of stem cell transplants, which are currently high-risk procedures often considered only as a last resort. Its pipeline includes several key product candidates, such as targeted antibody-drug conjugates for transplant conditioning, a novel stem cell mobilization agent, and allogeneic stem cell therapies. Magenta is also exploring collaborations to assess the effectiveness of its therapies in combination with existing treatments, such as gene therapies for sickle cell disease. Founded in 2015 and headquartered in Cambridge, Massachusetts, Magenta Therapeutics seeks to expand the curative potential of stem cell therapies to a broader patient population by addressing the toxicity and long-term side effects associated with current transplant methods.

Treeline Biosciences is a biotechnology company established in 2021 and based in Stamford, Connecticut. The company focuses on developing transformative precision medicines aimed at treating cancer and other serious health conditions. Utilizing a comprehensive drug discovery platform, Treeline combines mechanistic biology, medicinal chemistry, computational science, structural biology, and protein science to create innovative therapeutic solutions. Through its research and development efforts, Treeline aims to provide effective treatments to improve patient outcomes in oncology and beyond.

X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4, currently undergoing multiple clinical trials. These include a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as Phase Ib and Phase IIa trials focused on severe congenital neutropenia and clear cell renal cell carcinoma, respectively. In addition, X4 Pharmaceuticals is advancing X4P-002, targeting glioblastoma multiforme, and X4P-003 aimed at primary immune deficiencies. The company has also established a license agreement with Abbisko Therapeutics to develop mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.

Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) to treat hematologic and solid malignancies. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company utilizes a specialized platform that integrates gene editing and protein engineering to create allogeneic therapies. This platform allows for the generation of master cell banks of modified immune effector cells, specifically engineered to optimize performance and reduce the risk of rejection by the host immune system. By employing advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to address significant unmet medical needs in cancer and other diseases.

Gemini Therapeutics, Inc. is a precision medicine company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing new therapies for patients experiencing dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini Therapeutics focuses on genetically defined conditions, creating therapeutic candidates that address molecular abnormalities in patients with significant clinical needs. Their diverse pipeline encompasses monoclonal antibodies, recombinant proteins, and gene therapies, positioning the company to potentially introduce first-in-class therapeutics. The development of these innovative treatment options is supported by collaborations with leading life science investors and academic institutions worldwide, reflecting a commitment to advancing medical care for individuals suffering from these conditions.

Scorpion Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing next-generation precision oncology technologies for cancer treatment. Founded in 2020, the company specializes in creating targeted small-molecule drugs that interact with validated cancer targets. Its research encompasses therapies aimed at known oncogenes, previously undruggable cancer targets, and novel targets. By integrating technologies across target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics aims to advance a comprehensive pipeline of optimized compounds. The company's goal is to expand the reach of precision medicine, enabling healthcare professionals to offer innovative treatments to a broader range of cancer patients.

Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.

Q32 Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for severe autoimmune and inflammatory diseases. Established in 2017, the company aims to address immune system dysregulation, providing treatment options for conditions that currently have limited or inadequate therapies. Q32 Bio's pipeline includes ADX-914, a human anti-IL-7R antibody designed to re-regulate adaptive immune function, and ADX-097, which demonstrates effective distribution to affected tissues and robust efficacy. With a team of experienced scientists and industry professionals, Q32 Bio is dedicated to restoring healthy immune balance through novel biologic therapies that target critical pathways in both the innate and adaptive immune systems.

Nuvation Bio Inc. is a biopharmaceutical company dedicated to addressing unmet needs in oncology through the development of novel therapies for challenging cancers. Founded in 2018 and headquartered in New York, with an additional office in San Francisco, Nuvation Bio focuses on treating patients whose conditions have not responded to conventional treatments. The company's leading clinical-stage candidate, NUV-868, is a BD2-selective oral small molecule BET inhibitor that targets the BRD4 protein, which plays a crucial role in regulating tumor growth and differentiation. In addition to NUV-868, Nuvation Bio is advancing a proprietary small molecule Drug-Drug Conjugate platform aimed at enhancing therapeutic efficacy. The company’s comprehensive portfolio includes multiple drug development candidates designed to meet the specific needs of cancer patients.

Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery. Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies. Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.

CoreMap, Inc. is dedicated to enhancing patient outcomes through advanced diagnostic technology tailored for electrophysiologists treating atrial fibrillation. Founded in 2016 and based in Winooski, Vermont, the company has developed a micro-electrode solution that allows for sequential mapping of tissue properties. This innovative technology addresses critical challenges in atrial fibrillation treatment, specifically poor spatial resolution and inadequate sample density. CoreMap's ultra-high resolution electrodes provide detailed insights into cardiac activation, even in the presence of fibrillation, thereby enabling medical practitioners to offer more effective treatment options for patients.

MobileODT Ltd develops optical diagnostic devices and software services aimed at early cancer detection. The company offers the EVA COLPO, a portable and FDA-cleared colposcope that connects to the internet, making it easy for healthcare providers to conduct examinations. The EVA SANE system allows for the secure management of patient data, including photos and notes, on a HIPAA-compliant server. Additionally, the EVA WELL tool enhances gynecologic exams through digital visualization. MobileODT also provides a mobile application for remote image capture and patient information tracking, alongside a cloud-based portal for collaboration and reporting. Other products include Eviscope, designed for documenting violence and abuse, EviDx for case documentation, and EviCenter for managing patient data. Founded in 2012 and headquartered in Tel Aviv, Israel, with an office in New York, MobileODT has established a strong presence in markets such as the U.S., Africa, and India, having conducted over 40,000 procedures across 29 countries.

GentiBio, Inc. is a biotherapeutics company focused on developing engineered regulatory T cells (EngTregs) aimed at treating autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and headquartered in Boston, Massachusetts, with additional locations in Israel and Seattle, GentiBio utilizes a proprietary platform that combines autologous and allogeneic EngTregs technologies. This innovative approach is designed to restore immune tolerance and address limitations present in current regulatory T-cell therapies. By targeting the underlying causes of diseases related to immune system dysfunction, GentiBio aims to provide effective therapeutic solutions for conditions that arise from immune system overshooting or malfunctioning. The company was co-founded by experts in Treg biology and synthetic immunology, positioning it at the forefront of this emerging field.

PMV Pharmaceuticals, Inc. is a precision oncology company focused on the discovery and development of small molecule therapies targeting p53 mutations in cancer. Its lead candidate, PC14586, aims to correct and restore the function of the p53 protein, which is critical in regulating cell growth and preventing tumor formation. In addition to PC14586, the company is developing therapies for various p53 hotspot mutations, including the R273H mutation. Founded in 2013 and headquartered in Cranbury, New Jersey, PMV Pharmaceuticals leverages extensive expertise in p53 biology to advance its innovative treatment options for cancer patients.

Q32 Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for severe autoimmune and inflammatory diseases. Established in 2017, the company aims to address immune system dysregulation, providing treatment options for conditions that currently have limited or inadequate therapies. Q32 Bio's pipeline includes ADX-914, a human anti-IL-7R antibody designed to re-regulate adaptive immune function, and ADX-097, which demonstrates effective distribution to affected tissues and robust efficacy. With a team of experienced scientists and industry professionals, Q32 Bio is dedicated to restoring healthy immune balance through novel biologic therapies that target critical pathways in both the innate and adaptive immune systems.

TytoCare Ltd. is a healthcare technology company based in Netanya, Israel, with an additional office in New York, New York. Founded in 2011, TytoCare develops handheld devices and applications that facilitate on-demand medical examinations and diagnoses through virtual consultations with healthcare providers. Its product offerings include TytoHome for consumers, TytoPro for healthcare professionals, and TytoClinic for remote care locations. These solutions enable users to perform self-examinations of various body systems, including the heart, lungs, skin, and throat, while providing remote access to physicians for evaluation and treatment of common conditions such as ear infections, flu, and respiratory issues. The platform incorporates a cloud-based data repository, analytics, and machine learning algorithms, enhancing the accuracy and user experience of remote healthcare services. TytoCare has established a strategic partnership with Novant Health to further expand its reach in the telehealth market.

Pandion Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patients with autoimmune diseases and inflammatory conditions. The company's lead product candidate, PT101, is an engineered variant of interleukin-2 currently undergoing Phase 1a clinical trials for moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and PT001 and PT002, which are bifunctional molecules designed for tissue-selective immunomodulation in the gastrointestinal tract. These molecules utilize a unique approach to achieve localized treatment, potentially enhancing efficacy and safety compared to traditional therapies. Pandion also collaborates with Astellas Pharma to develop locally acting immunomodulators targeting autoimmune diseases of the pancreas. The company is headquartered in Watertown, Massachusetts.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative treatments for patients with hematological and musculoskeletal disorders that have significant unmet medical needs. The company's lead product candidate, KER-050, targets low blood cell counts, specifically anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis. Additionally, Keros is advancing KER-047, a small molecule therapy aimed at treating anemia caused by elevated hepcidin levels, as well as fibrodysplasia ossificans progressiva. Another candidate, KER-012, is being developed for conditions related to bone loss, such as osteoporosis and osteogenesis imperfecta, and for pulmonary arterial hypertension. Founded in 2015, Keros Therapeutics is headquartered in Lexington, Massachusetts.

Harmony Biosciences, established in 2017 and based in Plymouth Meeting, Pennsylvania, is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare neurological disorders. Its primary product, WAKIX (pitolisant), is a first-in-class medication designed to increase histamine signaling in the brain, approved for treating cataplexy in adult narcolepsy patients. Harmony Biosciences operates as a subsidiary of Harmony Biosciences Holdings, Inc., which is dedicated to addressing unmet medical needs in this therapeutic area.

PMV Pharmaceuticals, Inc. is a precision oncology company focused on the discovery and development of small molecule therapies targeting p53 mutations in cancer. Its lead candidate, PC14586, aims to correct and restore the function of the p53 protein, which is critical in regulating cell growth and preventing tumor formation. In addition to PC14586, the company is developing therapies for various p53 hotspot mutations, including the R273H mutation. Founded in 2013 and headquartered in Cranbury, New Jersey, PMV Pharmaceuticals leverages extensive expertise in p53 biology to advance its innovative treatment options for cancer patients.

Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.

Foamix Pharmaceuticals is a specialty pharmaceutical company based in Bridgewater, New Jersey, that focuses on the development and commercialization of proprietary topical drugs for dermatological conditions, as well as for ophthalmologic and gynecologic applications. Founded in 2014, the company utilizes its Molecule Stabilizing Technology platform to create innovative foam-based formulations. Its lead product, a first-in-class Topical Minocycline Foam, targets significant markets in dermatology and ophthalmology, having shown high efficacy and favorable safety in clinical trials for conditions such as acne and impetigo. Foamix's pipeline includes multiple drug candidates aimed at treating various skin conditions, including FMX101, FMX102, FMX103, and FDX104. The company is also engaged in development and licensing agreements with other pharmaceutical firms, enhancing its reach in the healthcare market.

Athenex, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for cancer and related conditions. Founded in 2003 and headquartered in Buffalo, New York, Athenex operates across North America and Asia, with a clinical pipeline that includes several promising product candidates. The company’s Orascovery platform features oral formulations of well-known chemotherapeutic agents such as Paclitaxel, Irinotecan, Docetaxel, Topotecan, and Eribulin, which are in various stages of clinical trials targeting multiple cancer types. Additionally, Athenex is developing Src Kinase inhibitors for skin cancers and psoriasis, as well as advanced immunotherapies and arginine deprivation therapies. Through its commitment to innovative research and collaborations, Athenex aims to become a leader in delivering effective cancer treatments and improving patient health outcomes globally.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines for underserved patient populations affected by rare diseases and cancer. The company employs a precision medicine approach and has a diverse portfolio of small molecule targeted oncology products. Its lead candidate, nirogacestat, an oral gamma secretase inhibitor, is currently in Phase III clinical trials for desmoid tumors. Additionally, SpringWorks is advancing several other product candidates, including mirdametinib, an oral MEK inhibitor in Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas, and various combinations involving nirogacestat for multiple myeloma. The company has established collaborations with organizations such as BeiGene, GlaxoSmithKline, and Allogene, aimed at enhancing the development of its therapies. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks is committed to unlocking the potential of its pipeline to provide innovative solutions for patients suffering from cancer and rare diseases.

Prevail Therapeutics Inc. is a biotechnology company headquartered in New York, specializing in the development and commercialization of gene therapies targeting neurodegenerative diseases. Founded in 2017, the company focuses on adeno-associated virus (AAV)-based therapies, with its lead candidate, PR001, currently undergoing Phase I/II clinical trials for Parkinson's disease associated with GBA1 mutations and neuronopathic Gaucher disease. Additionally, Prevail is advancing PR006 for frontotemporal dementia linked to GRN mutations and PR004 for various synucleinopathies. The company's mission is to provide disease-modifying treatments for patients suffering from these challenging conditions.

Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on developing and commercializing therapeutics for rare genetic disorders of hemoglobin, including sickle cell disease and beta-thalassemia. Founded in 2016, the company is advancing its lead product candidate, IMR-687, which is a highly selective small molecule inhibitor of PDE9. IMR-687 is designed as an oral, once-a-day treatment that aims to modify disease through a multimodal mechanism of action affecting various cell types, including red and white blood cells. Imara is dedicated to addressing the unmet medical needs of patients suffering from these serious hemoglobinopathies.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

Avedro, Inc. is a medical device and pharmaceutical company specializing in the treatment of corneal disorders, particularly corneal ectatic conditions and refractive errors. The company has developed the Avedro Corneal Remodeling platform, which includes the KXL and Mosaic systems that utilize ultraviolet A (UVA) light, alongside a range of single-use riboflavin drug formulations. These technologies are primarily aimed at treating progressive keratoconus and corneal ectasia following refractive surgery. Avedro also focuses on advancing the science of Thermo-biomechanics, exemplified by its Keraflex procedure, a non-invasive method for corneal reshaping that preserves the cornea's biomechanical integrity. The company's products are marketed to ophthalmologists, hospitals, and ambulatory surgery centers in the United States and through international distributors. Avedro, originally established as ThermalVision, Inc. in 2002, is headquartered in Waltham, Massachusetts, and operates as a subsidiary of Glaukos Corporation.

Foamix Pharmaceuticals is a specialty pharmaceutical company based in Bridgewater, New Jersey, that focuses on the development and commercialization of proprietary topical drugs for dermatological conditions, as well as for ophthalmologic and gynecologic applications. Founded in 2014, the company utilizes its Molecule Stabilizing Technology platform to create innovative foam-based formulations. Its lead product, a first-in-class Topical Minocycline Foam, targets significant markets in dermatology and ophthalmology, having shown high efficacy and favorable safety in clinical trials for conditions such as acne and impetigo. Foamix's pipeline includes multiple drug candidates aimed at treating various skin conditions, including FMX101, FMX102, FMX103, and FDX104. The company is also engaged in development and licensing agreements with other pharmaceutical firms, enhancing its reach in the healthcare market.

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for cancers linked to abnormal gene expression and drug resistance. The company specializes in the field of epigenetics, targeting selective regulators of epigenetic function that are vital for gene expression control. Its lead product candidates include CPI-0610, currently in Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is undergoing Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is advancing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial aimed at treating solid tumors. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Epigenetix, Inc. before rebranding in March 2008.

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of innovative therapies aimed at degrading disease-causing proteins. The company's lead product candidates include ARV-110, a proteolysis targeting chimera (PROTAC) currently in phase I clinical trials for metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. In addition to these, Arvinas is developing various other PROTACs aimed at degrading clinically relevant androgen receptor mutations and treatments for neurodegenerative diseases, including tauopathies. The company has established collaborations with prominent pharmaceutical firms such as Pfizer Inc., Genentech, and Bayer AG, enhancing its research capabilities and reach within the biopharmaceutical landscape. Founded in 2015, Arvinas aims to improve patient outcomes by eliminating harmful proteins from the body through its proprietary technology.

Prevail Therapeutics Inc. is a biotechnology company headquartered in New York, specializing in the development and commercialization of gene therapies targeting neurodegenerative diseases. Founded in 2017, the company focuses on adeno-associated virus (AAV)-based therapies, with its lead candidate, PR001, currently undergoing Phase I/II clinical trials for Parkinson's disease associated with GBA1 mutations and neuronopathic Gaucher disease. Additionally, Prevail is advancing PR006 for frontotemporal dementia linked to GRN mutations and PR004 for various synucleinopathies. The company's mission is to provide disease-modifying treatments for patients suffering from these challenging conditions.

TytoCare Ltd. is a healthcare technology company based in Netanya, Israel, with an additional office in New York, New York. Founded in 2011, TytoCare develops handheld devices and applications that facilitate on-demand medical examinations and diagnoses through virtual consultations with healthcare providers. Its product offerings include TytoHome for consumers, TytoPro for healthcare professionals, and TytoClinic for remote care locations. These solutions enable users to perform self-examinations of various body systems, including the heart, lungs, skin, and throat, while providing remote access to physicians for evaluation and treatment of common conditions such as ear infections, flu, and respiratory issues. The platform incorporates a cloud-based data repository, analytics, and machine learning algorithms, enhancing the accuracy and user experience of remote healthcare services. TytoCare has established a strategic partnership with Novant Health to further expand its reach in the telehealth market.

Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.

resTORbio, Inc. was a clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to developing novel therapeutics for aging-related diseases. The company focused on inhibiting the target of rapamycin complex 1 (TORC1), a pathway linked to the decline in various organ functions associated with aging. Its lead drug candidate, RTB101, is an oral, selective inhibitor of TORC1, which was undergoing Phase 1b/2a clinical trials for the treatment of Parkinson’s disease and neurodegenerative conditions. Additionally, resTORbio collaborated with TrialSpark to explore RTB101's potential for treating COVID-19. Founded in 2016, the company aimed to address a range of aging-related health issues, including cancer, heart disease, and diabetes. In September 2020, resTORbio was acquired by Adicet Bio, Inc. in a reverse merger transaction.

RDD Pharma, Ltd. is a pharmaceutical company based in Tel-Aviv, Israel, with an additional office in New York, New York. Founded in 2008, RDD Pharma focuses on the development and commercialization of targeted therapeutics for anorectal diseases and gastrointestinal disorders. The company specializes in creating innovative pharmacological treatments for conditions such as chronic anal fissures, fecal incontinence, and pruritus ani, particularly in patients with spinal cord injuries. RDD Pharma addresses the unique challenges of treating these conditions by employing specialized formulation and delivery techniques that cater to the anatomical and physiological variations in this sensitive area.

TELA Bio, Inc. is a medical technology company based in Malvern, Pennsylvania, established in 2012. The company specializes in the design, development, and marketing of tissue reinforcement materials aimed at addressing unmet needs in soft tissue reconstruction. TELA Bio offers a range of products, including the OviTex Reinforced Tissue Matrix, which is utilized in hernia repair and abdominal wall reconstruction, and the OviTex PRS Reinforced Tissue Matrix, designed for plastic and reconstructive surgery. Additionally, TELA Bio provides OviTex products specifically for laparoscopic and robotic-assisted surgical procedures, which are derived from ovine rumen and incorporate polypropylene fiber. The company's marketing efforts are primarily focused in the United States, utilizing a direct sales force to promote its innovative solutions in soft tissue repair.

Gemini Therapeutics, Inc. is a precision medicine company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing new therapies for patients experiencing dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini Therapeutics focuses on genetically defined conditions, creating therapeutic candidates that address molecular abnormalities in patients with significant clinical needs. Their diverse pipeline encompasses monoclonal antibodies, recombinant proteins, and gene therapies, positioning the company to potentially introduce first-in-class therapeutics. The development of these innovative treatment options is supported by collaborations with leading life science investors and academic institutions worldwide, reflecting a commitment to advancing medical care for individuals suffering from these conditions.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines for underserved patient populations affected by rare diseases and cancer. The company employs a precision medicine approach and has a diverse portfolio of small molecule targeted oncology products. Its lead candidate, nirogacestat, an oral gamma secretase inhibitor, is currently in Phase III clinical trials for desmoid tumors. Additionally, SpringWorks is advancing several other product candidates, including mirdametinib, an oral MEK inhibitor in Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas, and various combinations involving nirogacestat for multiple myeloma. The company has established collaborations with organizations such as BeiGene, GlaxoSmithKline, and Allogene, aimed at enhancing the development of its therapies. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks is committed to unlocking the potential of its pipeline to provide innovative solutions for patients suffering from cancer and rare diseases.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

MobileODT Ltd develops optical diagnostic devices and software services aimed at early cancer detection. The company offers the EVA COLPO, a portable and FDA-cleared colposcope that connects to the internet, making it easy for healthcare providers to conduct examinations. The EVA SANE system allows for the secure management of patient data, including photos and notes, on a HIPAA-compliant server. Additionally, the EVA WELL tool enhances gynecologic exams through digital visualization. MobileODT also provides a mobile application for remote image capture and patient information tracking, alongside a cloud-based portal for collaboration and reporting. Other products include Eviscope, designed for documenting violence and abuse, EviDx for case documentation, and EviCenter for managing patient data. Founded in 2012 and headquartered in Tel Aviv, Israel, with an office in New York, MobileODT has established a strong presence in markets such as the U.S., Africa, and India, having conducted over 40,000 procedures across 29 countries.

LogicBio Therapeutics is a genome editing company dedicated to developing innovative treatments for rare diseases, particularly those affecting pediatric patients with significant unmet medical needs. Utilizing its proprietary GeneRide technology, LogicBio aims to integrate corrective genes into patients' genomes, offering potential therapeutic benefits. The company's lead product candidate, LB-001, targets Methylmalonic Acidemia, a severe condition that manifests at birth. Additionally, LogicBio is advancing other candidates, including LB-301, which is being developed in collaboration with Takeda Pharmaceutical Company for Crigler-Najjar syndrome. The company also partners with the Children's Medical Research Institute to create new viral vectors. Founded in 2014 and based in Lexington, Massachusetts, LogicBio is focused on delivering safe and effective genetic medicine to patients suffering from previously untreatable genetic and infectious diseases.

Avitide, Inc. is a company that specializes in the discovery, manufacturing, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. Founded in 2012 and based in Lebanon, New Hampshire, Avitide focuses on enhancing the purification of therapeutic proteins through its innovative affinity separation technology. This technology helps clients streamline bioprocess development timelines, mitigate program risks, and lower manufacturing costs while ensuring scalability for commercial applications. The company develops customized solutions for a variety of life-saving therapeutics, including enzymes, multi-specific antibodies, gene therapies, and vaccines. By utilizing rapid development techniques for chromatography resins, Avitide aims to improve drug safety and establish bio-similarity in its offerings.

Tisbury Pharmaceuticals, Inc. is engaged in the discovery, development, and commercialization of therapies for the treatment of primary open angle glaucoma. Founded in 2017 and based in Beverly, Massachusetts, the company focuses on its clinical candidate, R-801, which aims to enhance fluid flow through the trabecular meshwork by utilizing redox catalysis and K+-ATP channel activation. This innovative approach targets the drainage openings in the eye, significantly reducing intraocular pressure in patients suffering from glaucoma.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

Avedro, Inc. is a medical device and pharmaceutical company specializing in the treatment of corneal disorders, particularly corneal ectatic conditions and refractive errors. The company has developed the Avedro Corneal Remodeling platform, which includes the KXL and Mosaic systems that utilize ultraviolet A (UVA) light, alongside a range of single-use riboflavin drug formulations. These technologies are primarily aimed at treating progressive keratoconus and corneal ectasia following refractive surgery. Avedro also focuses on advancing the science of Thermo-biomechanics, exemplified by its Keraflex procedure, a non-invasive method for corneal reshaping that preserves the cornea's biomechanical integrity. The company's products are marketed to ophthalmologists, hospitals, and ambulatory surgery centers in the United States and through international distributors. Avedro, originally established as ThermalVision, Inc. in 2002, is headquartered in Waltham, Massachusetts, and operates as a subsidiary of Glaukos Corporation.

Arsanis, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis develops mAbs targeting various bacterial and viral pathogens, including its lead program ASN100, which is focused on preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients and is currently in Phase 2 clinical trials. The company's pipeline also includes ASN500, targeting respiratory syncytial virus (RSV), as well as preclinical candidates ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Additionally, Arsanis operates research and preclinical development efforts in Vienna, Austria, through its subsidiary, Arsanis Biosciences GmbH. The company's advanced understanding of infection pathogenesis and mAb discovery techniques underpins its efforts to tackle significant health challenges posed by infectious diseases.

PMV Pharmaceuticals, Inc. is a precision oncology company focused on the discovery and development of small molecule therapies targeting p53 mutations in cancer. Its lead candidate, PC14586, aims to correct and restore the function of the p53 protein, which is critical in regulating cell growth and preventing tumor formation. In addition to PC14586, the company is developing therapies for various p53 hotspot mutations, including the R273H mutation. Founded in 2013 and headquartered in Cranbury, New Jersey, PMV Pharmaceuticals leverages extensive expertise in p53 biology to advance its innovative treatment options for cancer patients.

scPharmaceuticals Inc. is a pharmaceutical company focused on developing and commercializing innovative therapeutic options for patients with serious medical conditions. The company’s lead product candidate, Furoscix, features a proprietary buffered formulation of furosemide delivered via the SmartDose drug delivery system, targeting congestion in patients with decompensated heart failure. In addition to Furoscix, scPharmaceuticals is advancing its product pipeline with scCeftriaxone, an antibiotic for infections from gram-positive and gram-negative organisms, and its scCarbapenem program, aimed at treating infections caused by gram-negative organisms. Founded in 2013 and headquartered in Burlington, Massachusetts, scPharmaceuticals aims to provide a convenient, safe, and effective alternative to intravenous drug administration through subcutaneous delivery, addressing the associated costs and risks. The company collaborates with West Pharmaceutical Services, Inc. to enhance the SmartDose system for Furoscix.

Turnstone Biologics Inc. is a clinical-stage biotechnology company based in Ottawa, Canada, with an additional office in New York. Founded in 2015, the company is dedicated to advancing innovative viral immunotherapies aimed at improving cancer patient survival. Its lead product, RIVAL-01, utilizes a vaccinia virus backbone that encodes several immunomodulators, including Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine, which work together to enhance immune activity and optimize the tumor microenvironment for effective cancer treatment. Additionally, Turnstone Biologics is developing next-generation tumor-infiltrating lymphocyte (TIL) therapies by isolating and expanding the most potent and tumor-reactive T cells from patients' tumors, thereby harnessing the body's own immune system to combat solid tumors. Through these innovative approaches, Turnstone Biologics aims to deliver breakthrough cancer immunotherapies that significantly improve clinical outcomes for patients.

Gemini Therapeutics, Inc. is a precision medicine company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing new therapies for patients experiencing dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini Therapeutics focuses on genetically defined conditions, creating therapeutic candidates that address molecular abnormalities in patients with significant clinical needs. Their diverse pipeline encompasses monoclonal antibodies, recombinant proteins, and gene therapies, positioning the company to potentially introduce first-in-class therapeutics. The development of these innovative treatment options is supported by collaborations with leading life science investors and academic institutions worldwide, reflecting a commitment to advancing medical care for individuals suffering from these conditions.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye diseases using its proprietary Mucus Penetrating Particles (MPP) technology. This technology enhances drug distribution and pharmacokinetics by coating mucosal surfaces with biocompatible, drug-loaded particles, allowing for improved local drug concentrations while minimizing systemic exposure. Kala's lead product candidate, KPI-121 0.25%, has completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS has also completed two Phase III trials for managing inflammation and pain after ocular surgery. The company is advancing KPI-285, a receptor tyrosine kinase inhibitor, in preclinical studies targeting retinal diseases. Established in 2009 and headquartered in Watertown, Massachusetts, Kala Pharmaceuticals continues to explore diverse product opportunities while focusing on internal development and research collaborations to address significant clinical needs.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

LogicBio Therapeutics is a genome editing company dedicated to developing innovative treatments for rare diseases, particularly those affecting pediatric patients with significant unmet medical needs. Utilizing its proprietary GeneRide technology, LogicBio aims to integrate corrective genes into patients' genomes, offering potential therapeutic benefits. The company's lead product candidate, LB-001, targets Methylmalonic Acidemia, a severe condition that manifests at birth. Additionally, LogicBio is advancing other candidates, including LB-301, which is being developed in collaboration with Takeda Pharmaceutical Company for Crigler-Najjar syndrome. The company also partners with the Children's Medical Research Institute to create new viral vectors. Founded in 2014 and based in Lexington, Massachusetts, LogicBio is focused on delivering safe and effective genetic medicine to patients suffering from previously untreatable genetic and infectious diseases.

Avedro, Inc. is a medical device and pharmaceutical company specializing in the treatment of corneal disorders, particularly corneal ectatic conditions and refractive errors. The company has developed the Avedro Corneal Remodeling platform, which includes the KXL and Mosaic systems that utilize ultraviolet A (UVA) light, alongside a range of single-use riboflavin drug formulations. These technologies are primarily aimed at treating progressive keratoconus and corneal ectasia following refractive surgery. Avedro also focuses on advancing the science of Thermo-biomechanics, exemplified by its Keraflex procedure, a non-invasive method for corneal reshaping that preserves the cornea's biomechanical integrity. The company's products are marketed to ophthalmologists, hospitals, and ambulatory surgery centers in the United States and through international distributors. Avedro, originally established as ThermalVision, Inc. in 2002, is headquartered in Waltham, Massachusetts, and operates as a subsidiary of Glaukos Corporation.

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of innovative therapies aimed at degrading disease-causing proteins. The company's lead product candidates include ARV-110, a proteolysis targeting chimera (PROTAC) currently in phase I clinical trials for metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. In addition to these, Arvinas is developing various other PROTACs aimed at degrading clinically relevant androgen receptor mutations and treatments for neurodegenerative diseases, including tauopathies. The company has established collaborations with prominent pharmaceutical firms such as Pfizer Inc., Genentech, and Bayer AG, enhancing its research capabilities and reach within the biopharmaceutical landscape. Founded in 2015, Arvinas aims to improve patient outcomes by eliminating harmful proteins from the body through its proprietary technology.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

Intellia Therapeutics, Inc. is a genome editing company headquartered in Cambridge, Massachusetts, specializing in the development of therapeutics using the CRISPR/Cas9 technology. This innovative platform allows for precise alterations of genomic DNA, enabling the company to pursue treatments for a range of severe and life-threatening diseases. Intellia's pipeline includes both in vivo programs targeting liver diseases such as transthyretin amyloidosis and hereditary angioedema, as well as ex vivo programs focused on engineered cell therapies for oncological and autoimmune disorders. The company is also exploring treatments for conditions like primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Intellia has established collaborations with several organizations, enhancing its research and development capabilities. Founded in 2014, Intellia holds a significant intellectual property portfolio related to the therapeutic applications of CRISPR/Cas9, aiming to address high unmet medical needs through its advanced gene-editing approaches.

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of therapies for cancer treatment. The company's lead candidate, entinostat, is a class I HDAC inhibitor currently in Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, Syndax is advancing SNDX-5613, a selective inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for acute myeloid leukemia with specific mutations. The company also explores entinostat in combination with immunotherapies such as Keytruda and Tecentriq for various cancers, including non-small cell lung cancer and metastatic breast cancer. Furthermore, Syndax is developing axatilimab, a monoclonal antibody targeting the CSF-1 receptor, currently in trials for chronic graft-versus-host disease. The company maintains collaborative relationships with several major pharmaceutical entities and research organizations to enhance its drug development efforts. Founded in 2005, Syndax Pharmaceuticals is committed to advancing innovative treatments for patients with challenging malignancies.

Rhythm Metabolic is the subsidiary of Rhythm Pharmaceuticals that develops setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway. It was established in 2013 and is headquartered in Boston, Massachusetts.

Avitide, Inc. is a company that specializes in the discovery, manufacturing, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. Founded in 2012 and based in Lebanon, New Hampshire, Avitide focuses on enhancing the purification of therapeutic proteins through its innovative affinity separation technology. This technology helps clients streamline bioprocess development timelines, mitigate program risks, and lower manufacturing costs while ensuring scalability for commercial applications. The company develops customized solutions for a variety of life-saving therapeutics, including enzymes, multi-specific antibodies, gene therapies, and vaccines. By utilizing rapid development techniques for chromatography resins, Avitide aims to improve drug safety and establish bio-similarity in its offerings.

TytoCare Ltd. is a healthcare technology company based in Netanya, Israel, with an additional office in New York, New York. Founded in 2011, TytoCare develops handheld devices and applications that facilitate on-demand medical examinations and diagnoses through virtual consultations with healthcare providers. Its product offerings include TytoHome for consumers, TytoPro for healthcare professionals, and TytoClinic for remote care locations. These solutions enable users to perform self-examinations of various body systems, including the heart, lungs, skin, and throat, while providing remote access to physicians for evaluation and treatment of common conditions such as ear infections, flu, and respiratory issues. The platform incorporates a cloud-based data repository, analytics, and machine learning algorithms, enhancing the accuracy and user experience of remote healthcare services. TytoCare has established a strategic partnership with Novant Health to further expand its reach in the telehealth market.

Symbiomix Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for women's health infections, particularly bacterial vaginosis (BV). Founded in 2012 and headquartered in Newark, New Jersey, with additional offices in Baltimore, Maryland, and Hamden, Connecticut, the company specializes in the development of its lead product, Solosec (secnidazole), a next-generation 5-nitroimidazole antibiotic designed for a convenient one-dose treatment. This drug offers enhanced pharmacokinetic properties that improve efficacy and tolerability for patients. Symbiomix is supported by prominent healthcare venture capital firms and aims to address the unmet therapeutic needs in the field of gynecologic infections. Since October 2017, it has operated as a subsidiary of Lupin Inc.

GENEWIZ, Inc. is a global contract research organization specializing in genomics and DNA sequencing services. Founded in 1999 and headquartered in South Plainfield, New Jersey, the company serves a diverse clientele, including pharmaceutical, biotechnology, academic, agricultural, clinical, and government institutions. GENEWIZ offers a comprehensive range of services, including Sanger DNA sequencing, gene synthesis, molecular biology techniques, genomic mutation analysis, and bioinformatics, all designed to enhance research productivity and efficiency. The company is also equipped to provide regulatory-compliant laboratory services for FDA applications, including RNA/DNA identity studies and SNP testing. With a focus on delivering high-quality data and exceptional technical support, GENEWIZ is committed to accelerating scientific discovery and advancing translational medicine. The company operates multiple locations across the United States and internationally in China, the United Kingdom, France, Germany, and Japan, solidifying its position as a preferred partner in the life sciences sector. As of November 2018, GENEWIZ operates as a subsidiary of Brooks Automation, Inc.

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the discovery and development of anticalin-based drugs. Anticalins are engineered proteins derived from naturally occurring lipocalins, which have the ability to bind and transport a variety of molecules. The company's clinical pipeline includes PRS-060, a drug candidate in Phase I trials for asthma and inflammatory diseases, and PRS-343, a bispecific protein also in Phase I trials for oncology. Additionally, Pieris is advancing PRS-344, a bispecific anticalin-antibody fusion protein in preclinical development, and PRS-080, which targets hepcidin for treating iron deficiency in patients with chronic kidney disease, currently in Phase IIa trials. Pieris has established strategic partnerships with several organizations, including Les Laboratoires Servier and AstraZeneca, and engages in research collaborations with academic institutions such as the University of Pittsburgh. The company was incorporated in 2000 and aims to address high unmet medical needs across various therapeutic areas, including cancer and severe asthma.

PMV Pharmaceuticals, Inc. is a precision oncology company focused on the discovery and development of small molecule therapies targeting p53 mutations in cancer. Its lead candidate, PC14586, aims to correct and restore the function of the p53 protein, which is critical in regulating cell growth and preventing tumor formation. In addition to PC14586, the company is developing therapies for various p53 hotspot mutations, including the R273H mutation. Founded in 2013 and headquartered in Cranbury, New Jersey, PMV Pharmaceuticals leverages extensive expertise in p53 biology to advance its innovative treatment options for cancer patients.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary platform utilizes advances in immunobiology and nanotechnology to create targeted immunomodulatory nanoparticles. Selecta's lead product, SEL-212, has successfully completed Phase II clinical trials for chronic refractory gout. Additionally, the company is advancing gene therapy candidates in preclinical development for rare metabolic disorders, including SEL-302 for methylmalonic acidemia and SEL-313 for ornithine transcarbamylase deficiency. Founded in 2007 and headquartered in Watertown, Massachusetts, Selecta Biosciences has established collaborations with various organizations, including Spark Therapeutics and the Massachusetts Institute of Technology, to enhance its research and development capabilities.

Loxo Oncology, Inc. is a biopharmaceutical company based in Stamford, Connecticut, focused on developing and commercializing targeted therapies for genetically defined cancers in the United States. Founded in 2013, the company aims to bring innovative cancer treatments to the clinic by identifying actionable "driver mutations" in tumors. Its lead product candidate, larotrectinib, is an oral selective inhibitor of tropomyosin receptor kinase (TRK) and is undergoing various clinical trials for multiple cancer types, including lung, melanoma, and breast cancer. Loxo Oncology is also advancing several preclinical programs, including candidates targeting RET fusion proteins and FGFR isoforms. The company has established collaborations with several organizations to enhance its drug discovery efforts and optimize its clinical development strategies. As a subsidiary of Eli Lilly and Company, Loxo Oncology is dedicated to creating effective therapies that address specific genetic vulnerabilities in cancer patients.

TytoCare Ltd. is a healthcare technology company based in Netanya, Israel, with an additional office in New York, New York. Founded in 2011, TytoCare develops handheld devices and applications that facilitate on-demand medical examinations and diagnoses through virtual consultations with healthcare providers. Its product offerings include TytoHome for consumers, TytoPro for healthcare professionals, and TytoClinic for remote care locations. These solutions enable users to perform self-examinations of various body systems, including the heart, lungs, skin, and throat, while providing remote access to physicians for evaluation and treatment of common conditions such as ear infections, flu, and respiratory issues. The platform incorporates a cloud-based data repository, analytics, and machine learning algorithms, enhancing the accuracy and user experience of remote healthcare services. TytoCare has established a strategic partnership with Novant Health to further expand its reach in the telehealth market.

SAGE Therapeutics is a biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders. The company's lead product is ZULRESSO, an intravenous formulation of brexanolone designed for treating postpartum depression. SAGE's pipeline includes several advanced candidates, such as SAGE-217, currently in Phase III trials for various depressive disorders and anxiety, and SAGE-324, which is in Phase II trials for essential tremors. Additionally, SAGE-718 is being explored for multiple conditions, including depression and Alzheimer's disease, having completed its Phase I trials. The company has established strategic collaborations with Shionogi & Co., Ltd. and Biogen Inc. to enhance the development and commercialization of its therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts, SAGE Therapeutics aims to address significant unmet needs in brain health through its scientific innovations and partnerships.

Loxo Oncology, Inc. is a biopharmaceutical company based in Stamford, Connecticut, focused on developing and commercializing targeted therapies for genetically defined cancers in the United States. Founded in 2013, the company aims to bring innovative cancer treatments to the clinic by identifying actionable "driver mutations" in tumors. Its lead product candidate, larotrectinib, is an oral selective inhibitor of tropomyosin receptor kinase (TRK) and is undergoing various clinical trials for multiple cancer types, including lung, melanoma, and breast cancer. Loxo Oncology is also advancing several preclinical programs, including candidates targeting RET fusion proteins and FGFR isoforms. The company has established collaborations with several organizations to enhance its drug discovery efforts and optimize its clinical development strategies. As a subsidiary of Eli Lilly and Company, Loxo Oncology is dedicated to creating effective therapies that address specific genetic vulnerabilities in cancer patients.

Arsanis, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis develops mAbs targeting various bacterial and viral pathogens, including its lead program ASN100, which is focused on preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients and is currently in Phase 2 clinical trials. The company's pipeline also includes ASN500, targeting respiratory syncytial virus (RSV), as well as preclinical candidates ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Additionally, Arsanis operates research and preclinical development efforts in Vienna, Austria, through its subsidiary, Arsanis Biosciences GmbH. The company's advanced understanding of infection pathogenesis and mAb discovery techniques underpins its efforts to tackle significant health challenges posed by infectious diseases.

Avitide, Inc. is a company that specializes in the discovery, manufacturing, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. Founded in 2012 and based in Lebanon, New Hampshire, Avitide focuses on enhancing the purification of therapeutic proteins through its innovative affinity separation technology. This technology helps clients streamline bioprocess development timelines, mitigate program risks, and lower manufacturing costs while ensuring scalability for commercial applications. The company develops customized solutions for a variety of life-saving therapeutics, including enzymes, multi-specific antibodies, gene therapies, and vaccines. By utilizing rapid development techniques for chromatography resins, Avitide aims to improve drug safety and establish bio-similarity in its offerings.

Whale Imaging Inc. manufactures medical imaging devices, specializing in surgical imaging systems and ultrasound systems. Its product line includes G-Arm products, such as the G-Arm B6 Duo and G-Arm GXi 2, as well as portable ultrasound devices like the Lambda P9 and Sigma P5. In addition to manufacturing, Whale Imaging offers training, preventative maintenance, and support services to ensure optimal use of its products. Founded in 1998, the company is headquartered in Beijing's hi-tech enterprise zone, with research and development facilities being established in Boston, Massachusetts. Whale Imaging underwent a strategic revitalization in 2008 under the leadership of Sean Zhu.

Intercept Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for progressive non-viral liver diseases in the United States, Europe, and Canada. Its primary product, Ocaliva, is a farnesoid X receptor agonist approved for the treatment of primary biliary cholangitis (PBC) in adults, often used in combination with ursodeoxycholic acid. The company is also exploring Ocaliva for other conditions, including nonalcoholic steatohepatitis (NASH), and has several additional product candidates in various stages of clinical and preclinical development. Intercept has established partnerships for research and commercialization, including agreements with Sumitomo Dainippon Pharma to develop OCA for PBC and NASH in Japan and China, as well as Aralez Pharmaceuticals Canada to develop bezafibrate in the United States. The company employs various marketing strategies, utilizing an internal commercial team, contract sales organizations, and third-party distributors. Founded in 2002, Intercept Pharmaceuticals is headquartered in New York, New York.